Literature DB >> 5309510

A collaborative study of heparins from different sources.

D R Bangham, P M Woodward.   

Abstract

Until about 10 years ago heparin was prepared from ox lungs and was regarded as a homogeneous polymer (of a sulfated mucopolysaccharide) with a relatively constant biological activity of about 100 IU/mg. The mucus and mucosa of the intestine of hog, sheep and ox have now become the main industrial source of bulk starting material. Preparations from this new source have much higher specific biological activity and have been shown to consist of mixtures of components with a number of different chemical and physical characteristics. It had been variously reported that preparations of heparins from the 2 sources gave significantly different estimates when bioassayed by the 2 different pharmacopoeial assay methods which are in wide use. If this is in fact the case these discrepancies could cause trouble in commerce, national control and clinical usage.This paper describes an international collaborative study to investigate this and other problems in the assay of heparin. In this study preparations of heparin made from the intestinal mucosa of each of 3 species (hog, sheep and ox) were biossayed with the International Standard for Heparin (from ox lung) established in 1958. Two of these preparations were national standards.The results showed differences between the estimated relative potencies of heparins of lung and mucosal origin, but they were not so consistent as to necessitate a separate international standard for each, although the imprecision of the assays may have concealed significant heterogeneity arising from real differences between the preparations. A further problem brought to light in this study was that, with the 2 pharmacopoeial assay methods in wide use, simple replicate assays using the same substrate gave estimates so precise that an analysis of variance on them was meaningless, whereas estimates between laboratories or with different substrate batches could vary by as much as 40%-50%.It is suggested that estimates of the biological activity of heparin preparations should be based on several independent assays using different batches of substrate.The biological assay methods currently used were devised some 15-20 years ago and, in the light of modern knowledge of mechanisms of blood clotting, are regarded as unsatisfactory in a number of respects. It is hoped that research into the mechanism of action of heparin will lead to improved methods of assay.

Entities:  

Mesh:

Substances:

Year:  1970        PMID: 5309510      PMCID: PMC2427503     

Source DB:  PubMed          Journal:  Bull World Health Organ        ISSN: 0042-9686            Impact factor:   9.408


  6 in total

1.  The assay of heparin.

Authors:  J PRITCHARD
Journal:  J Pharm Pharmacol       Date:  1956-07       Impact factor: 3.765

2.  A modified method for the colorimetric determination of heparin.

Authors:  L B Jaques; A Wollin
Journal:  Can J Physiol Pharmacol       Date:  1967-09       Impact factor: 2.273

3.  The second international standard for serum gonadotrophin.

Authors:  D R Bangham; P M Woodward
Journal:  Bull World Health Organ       Date:  1966       Impact factor: 9.408

4.  Heterogeneity of heparin.

Authors:  P L Walton; C R Ricketts; D R Bangham
Journal:  Br J Haematol       Date:  1966-05       Impact factor: 6.998

5.  An investigation of the assay of heparin based on its activity in vivo.

Authors:  W E Rezansoff; L B Jaques
Journal:  Thromb Diath Haemorrh       Date:  1967-08-15

6.  The Second International Standard for heparin.

Authors:  D R BANGHAM; M V MUSSETT
Journal:  Bull World Health Organ       Date:  1959       Impact factor: 9.408

  6 in total
  2 in total

1.  Standardization of diagnostic materials. 3. Laboratory reagents and coagulation assay procedures.

Authors:  E A Loeliger
Journal:  Bull World Health Organ       Date:  1973-06       Impact factor: 9.408

Review 2.  Protamine--antagonist to heparin.

Authors:  L B Jaques
Journal:  Can Med Assoc J       Date:  1973-05-19       Impact factor: 8.262

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.